How to Secure Medical Device Software Updates
Post Summary
99% of healthcare organizations have known device vulnerabilities, 53% of connected medical devices contain known critical vulnerabilities, and 33% of healthcare IoT devices have critical risks that could disrupt operations or compromise device functionality. Medical devices remain in clinical use for 10 to 15 years — far outlasting the support lifecycles of their software components — while only 22% of healthcare organizations run up-to-date software across all equipment. 276 million health records were exposed in 2024. A compromised software update can alter device function, corrupt patient data, or cause life-threatening clinical failures, as the 2020 SolarWinds attack demonstrated when malware embedded in an OTA patch infected 18,000 organizations.
A comprehensive device inventory must be established first, followed by penetration testing and vulnerability scanning to identify specific weaknesses. CVSS scores should be used to categorize vulnerabilities by severity and exploitability, and findings must be cross-referenced against the CISA Known Exploited Vulnerabilities list to identify threats currently being actively exploited. Third-party components including open-source libraries and off-the-shelf applications must be assessed for supply chain vulnerabilities. All backdoors left for development or testing must be confirmed disabled in production. Updates must be validated in a controlled environment before deployment. Vulnerabilities should be classified as either controlled risk — low likelihood of causing harm — or uncontrolled risk — high potential for patient safety or data integrity impact — to prioritize remediation.
A Software Bill of Materials is a structured inventory listing every software component in a device — open-source libraries, third-party code, and off-the-shelf applications — with supplier name, component name, version, unique identifier, dependency relationships, author, and timestamp. The FDA's June 2025 updated guidance treats SBOMs as essential cybersecurity documentation for connected devices, and Section 524B of the FD&C Act allows the FDA to reject premarket submissions lacking sufficient SBOM documentation. SBOMs must be provided in machine-readable formats such as SPDX or CycloneDX, must be updated with every software release or patch, and should be integrated into CI/CD pipelines for automated vulnerability cross-referencing against the National Vulnerability Database. In early 2025, a $9.8 million False Claims Act settlement against Illumina followed allegations of misrepresented cybersecurity capabilities for federally funded sequencing platforms.
Secure over-the-air update delivery requires three principles: authenticity ensuring updates come from a trusted source, integrity verifying updates are unchanged, and confidentiality preventing unauthorized access or reverse-engineering. Firmware images must be cryptographically signed using a private key stored in an HSM and verified with a corresponding public key before installation. TLS 1.3 should be used for transmission with JSON Web Signature for signing and SHA-256 for integrity verification. Anti-rollback protection stores the current firmware version in tamper-proof storage such as hardware fuses to block installation of outdated firmware. Secure boot mechanisms validate firmware signatures at every startup. A multi-tier key model including root and signing keys should establish a chain of trust, with root keys protected using TPM, SGX, or HSMs. An A/B partition scheme writes updates to an inactive slot and activates only after successful verification, reducing interruption risk.
Section 524B of the FD&C Act has mandated cybersecurity standards for all internet-connected medical devices since March 29, 2023. The FDA's Refuse to Accept policy has rejected noncompliant submissions since October 1, 2023, and noncompliance with postmarket requirements is a prohibited act under Section 301(q) of the FD&C Act. Updates must be classified based on cybersecurity impact — changes that affect cybersecurity versus those that do not — determining the documentation level required. Required documentation includes a machine-readable and human-readable SBOM, a Secure Product Development Framework record covering design through support, risk assessments for each modification, and device labeling with clear secure configuration instructions. A Coordinated Vulnerability Disclosure policy is mandatory under Section 524B, requiring contact information on labeling, clear timelines for validating and patching reported vulnerabilities, and collaboration with security researchers and healthcare facilities.
Censinet RiskOps™ centralizes medical device vulnerability tracking, automates risk prioritization, and monitors remediation efforts across device ecosystems, providing real-time dashboards of vulnerabilities, patch statuses, and compliance gaps. Censinet AI™ accelerates security questionnaires, generates automatic documentation summaries, and validates evidence — reducing assessment time without compromising accuracy. For IEC 62304 Class C devices posing risks of death or serious injury, automated tools flag high-priority vulnerabilities and route them to designated reviewers for final approval, maintaining human oversight at the highest-consequence decision points. Benchmarking capabilities enable organizations to compare cybersecurity performance against industry standards and peer organizations. The platform supports postmarket surveillance requirements under current FDA guidance and connects organizations to collaborative risk networks for sharing vulnerability data with the FDA and other manufacturers.
Securing medical device software updates is critical for patient safety and cybersecurity. Cyberattacks targeting healthcare devices can lead to compromised patient data, operational disruptions, or even life-threatening consequences. Here's what you need to know:
Medical Device Cybersecurity Statistics and Key Security Steps
Cybersecurity in Medical Devices – What QA/RA Must Do Today
sbb-itb-535baee
Conduct a Risk Assessment
Before rolling out any software update, it's essential to evaluate potential risks. This step acts as a critical safeguard against vulnerabilities that could compromise patient safety or expose sensitive health data. With 53% of connected medical devices in hospitals containing known critical vulnerabilities [2], skipping this process isn't an option.
Start by creating a complete inventory of your devices. Then, perform security assessments like penetration testing and vulnerability scanning to uncover potential weaknesses. Frameworks such as the Playbook for Threat Modeling Medical Devices can help identify specific attack vectors that could target your technology [1][2]. This process helps distinguish between controlled risks, which pose minimal harm, and uncontrolled risks, which could severely impact patient safety or data integrity [2].
"MedTech cybersecurity is not just about protecting data; it's about safeguarding human lives. Compromised devices could cause harm to a patient, misdiagnosis, or delayed diagnosis."
– Christian Espinosa, Founder and CEO,
Identify Vulnerabilities and Threats
Building on your initial assessment, systematically pinpoint vulnerabilities using established tools and frameworks. The Common Vulnerability Scoring System (CVSS) is particularly useful for categorizing and prioritizing security flaws based on their severity and exploitability. Cross-reference your findings with the CISA Known Exploited Vulnerabilities (KEV) list to identify threats that attackers are actively exploiting.
Don't overlook third-party components like external software or off-the-shelf applications, as these can introduce supply chain vulnerabilities. For instance, in March 2022, the FDA issued guidance to address vulnerabilities in the PTC Axeda agent and Axeda Desktop Server, recommending upgrades to Axeda agent Version 6.9.2 build 1049 or higher and limiting the agent’s configuration to local host interfaces [1][3].
Medical devices often remain in use for 10 to 15 years, far outlasting the support lifecycle of their software [2]. This longevity makes it crucial to address not only current vulnerabilities but also potential risks that could emerge as software ages. Alarmingly, 33% of healthcare IoT devices have critical risks that could disrupt operations or compromise device functionality [2].
Ensure that any backdoors left for development or testing purposes are fully disabled in production versions. Additionally, validate all software changes, updates, and patches in a controlled environment before deployment to ensure they don't negatively impact device safety or performance [3].
Create a Software Bill of Materials (SBOM)
An SBOM is a powerful tool for managing software risks throughout a device's lifecycle. It lists every software component - covering open-source libraries, third-party code, and off-the-shelf software - giving you the visibility needed to uncover hidden vulnerabilities. A well-maintained SBOM not only simplifies vulnerability tracking but also strengthens your risk assessment process. On June 27, 2025, the FDA released updated guidance titled "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions," emphasizing the importance of SBOMs for connected devices [4].
"The SBOM has moved from 'nice-to-have' to essential cybersecurity documentation for medical device submissions."
– Viktor Petersson, CEO, sbomify
Document each software component with details like supplier name, component name, version, unique identifier, dependency relationships, author, and timestamp. Use machine-readable formats like SPDX or CycloneDX to ensure consistency [4]. Remember, an SBOM is a dynamic document that must be updated with every software release or patch.
By assigning unique identifiers to each component, you can cross-check them with the National Vulnerability Database (NVD) to detect known security issues. Integrate SBOM generation into your CI/CD pipelines so that updates are automatically scanned for vulnerabilities, reducing the risk of introducing outdated or unsupported components [4]. Under Section 524B of the FD&C Act, the FDA can reject premarket submissions for devices that lack sufficient SBOM and cybersecurity documentation [4]. For example, in early 2025, the U.S. Department of Justice settled a $9.8 million False Claims Act case with Illumina after allegations that the company misrepresented its cybersecurity capabilities when selling sequencing platforms to federally funded institutions [2].
Platforms like Censinet RiskOps™ can simplify medical device risk assessments by centralizing vulnerability tracking, automating risk prioritization, and monitoring remediation efforts across your entire device ecosystem.
With a thorough risk assessment and SBOM in place, the next focus should be securing the update delivery process.
Implement Secure Update Delivery Mechanisms
This section emphasizes the importance of safeguarding update delivery, especially after completing a risk assessment and establishing a Software Bill of Materials (SBOM). The 2020 SolarWinds attack serves as a stark reminder of the risks involved - threat actors managed to infect 18,000 companies by embedding malware into an over-the-air (OTA) software patch [6]. For medical devices, where patient safety is critical, a compromised update could result in dire consequences.
"A secure Over-the-Air (OTA) update mechanism is the process of delivering new firmware to a device in a way that protects the integrity and authenticity of the software. It is the only practical way to patch security vulnerabilities discovered after a product has been shipped."
– Secure by Design Handbook
The foundation of secure update delivery relies on three key principles: authenticity (ensuring updates come from a trusted source), integrity (verifying updates remain unchanged), and confidentiality (preventing unauthorized access or reverse-engineering). With only 22% of healthcare organizations running up-to-date software across all equipment [6], implementing strong delivery mechanisms is crucial.
Use Encryption and Authentication Protocols
To ensure secure updates, firmware images should be signed using a private key stored securely (e.g., in a Hardware Security Module, or HSM) and verified with a corresponding public key. This process ensures that only authorized updates are installed. For secure communication, protocols like TLS 1.3 should be used, along with standards such as JSON Web Signature (JWS – RFC 7515) for signing and SHA-256 for integrity verification. Encrypting the update package using symmetric encryption can also help protect intellectual property and prevent reverse-engineering.
Securing the transmission channel is equally important. Establishing a chain of trust with a multi-tier key model - including root and signing keys - adds another layer of security. Root keys can be protected on devices using Trusted Platform Modules (TPM), Software Guard Extensions (SGX), or HSMs. For example, services like Azure IoT Hub generate signed update manifests that include file hashes, allowing devices to verify the integrity of downloaded binaries. Anti-rollback protection is another essential measure - this involves storing the current firmware version in tamper-proof storage (e.g., hardware fuses) to block outdated firmware. Additionally, secure boot mechanisms validate firmware signatures during every startup, with modern implementations requiring fewer resources [6].
Regulatory frameworks, such as the Cyber-Resilience Act (CRA), and advancements in post-quantum cryptography highlight the need to stay prepared for evolving threats [6].
Establish Secure Communication Channels
Securing the communication pathway requires a well-thought-out network architecture and stringent access controls. An A/B partition scheme can enhance reliability by writing updates to an inactive slot and activating them only after successful verification, reducing the risk of interruptions. Devices should also perform hostname verification during the TLS handshake to ensure they are connecting to a legitimate update server. Further, isolating update agent components by running them under dedicated accounts and restricting network communications to localhost can help minimize vulnerabilities.
"The risk of an attacker compromising the OTA update server and pushing a malicious update to the entire fleet is greater than the risk of an individual device being exploited by a local attacker."
– Secure by Design Handbook
To mitigate this risk, harden your update server and cloud infrastructure against unauthorized access that could lead to malicious firmware distribution. Automated network monitoring can quickly detect and address suspicious activity or tampered updates across your Internet of Medical Things (IoMT) network. If updates are delivered through intermediaries - such as a technician's laptop or a mobile app via Bluetooth or USB - ensure that these "last hop" connections are as secure as the primary transmission channel.
Platforms like Censinet RiskOps™ can help healthcare organizations manage their medical device ecosystems by centralizing vulnerability tracking and monitoring remediation efforts. This approach ensures that secure update delivery mechanisms remain effective throughout a device's lifecycle.
Once secure delivery channels are in place, the next step is to develop and rigorously test update procedures to maintain device integrity in real-world conditions.
Develop and Test Update Procedures
Once you've set up secure delivery channels, the next step is creating a solid process for validating software updates. This step ensures updates not only enhance device security but also avoid introducing new weaknesses. It's about maintaining the balance between improving functionality and safeguarding device integrity.
Apply Risk-Based Patch Management
Not every patch carries the same level of urgency. A risk-based approach allows you to focus on what matters most by categorizing updates into two groups: "controlled risk" (low likelihood of causing harm) and "uncontrolled risk" (high potential for safety or data threats) [2]. This prioritization ensures critical vulnerabilities are addressed first, minimizing potential risks.
Perform Testing and Validation
Once patches are prioritized, thorough testing is key to ensuring updates don’t inadvertently create new issues. Each update should go through detailed validation before being rolled out. For high-risk medical devices, such as those classified under IEC 62304 Class C, manufacturers should aim for 100% statement coverage, branch coverage, and modified condition/decision coverage (MC/DC) as a baseline [7].
To ensure comprehensive testing, establish bidirectional traceability. This means linking requirements, design specs, code modules, and test cases so that every security requirement is fully tested, and every code change is traceable back to its original purpose. This approach not only improves reliability but also provides a clear audit trail for compliance and quality assurance.
Ensure Compliance with FDA Guidelines
Regulatory compliance is a cornerstone of maintaining secure update procedures for connected medical devices. As of March 29, 2023, Section 524B of the FD&C Act mandates cybersecurity standards for all internet-connected medical devices [1][10]. Starting October 1, 2023, the FDA began enforcing a "Refuse to Accept" policy, rejecting submissions that fail to meet these standards [10].
The FDA's guidance from February 3, 2026, emphasizes that cybersecurity is a critical part of device safety and quality management [8]. This means update processes must be integrated into your Quality Management System (QMS) and adhere to applicable standards. Non-compliance isn't just a procedural issue - it’s a prohibited act under section 301(q) of the FD&C Act [8].
Document Update Processes
Updates must be classified based on their cybersecurity impact. The FDA requires a clear distinction between changes that affect cybersecurity and those that do not [8][10]. This categorization determines the level of documentation needed for premarket or postmarket submissions.
Key documentation requirements include:
"The primary goal of using an SPDF is to manufacture and maintain safe and effective devices. From a security standpoint, these are also trustworthy and resilient devices."
– U.S. Food and Drug Administration
To demonstrate compliance, align your processes with recognized standards like ANSI/AAMI SW96, AAMI TIR57, or IEC 81001-5-1 [8][9]. Inadequate labeling or unclear instructions can lead to your device being labeled as "misbranded." These practices should seamlessly integrate into your QMS for ongoing oversight and accountability.
Adopt Coordinated Vulnerability Disclosure (CVD) Practices
Under Section 524B, a Coordinated Vulnerability Disclosure (CVD) policy is now required for all connected medical devices [8][10]. This policy ensures collaboration with security researchers, healthcare facilities, and regulatory bodies to address vulnerabilities promptly.
Your CVD policy should include:
"Healthcare facilities require clear, timely information about vulnerabilities, available patches, and recommended configurations."
– Christian Espinosa, Founder and CEO, Blue Goat Cyber
Transparency and timely disclosure aren’t just best practices - they’re legal obligations with potential financial repercussions. By embedding CVD procedures into your QMS, you ensure these practices become a standard part of your design controls. This approach not only supports compliance but also fosters trust with healthcare providers relying on your devices for patient care.
Incorporating detailed documentation, risk assessments, and a robust CVD policy strengthens both regulatory adherence and device security throughout the product's lifecycle.
Use Risk Management Solutions for Lifecycle Oversight
Keeping medical devices secure throughout their lifecycle requires more than manual tracking - it calls for continuous oversight, automated processes, and integration with your Quality Management System (QMS) as outlined in IEC 62304 [11]. The sheer volume and complexity of vulnerabilities in connected devices make manual efforts impractical. Centralized risk management platforms fill this gap by automating repetitive tasks, while still relying on human oversight to ensure patient safety. These platforms seamlessly integrate with your existing QMS, providing traceability across all stages - planning, development, and postmarket surveillance - while staying aligned with global standards like IEC 62304 [11].
Automate Risk Assessments
Automation has revolutionized how healthcare organizations handle risk assessments for medical devices. Tools like Censinet RiskOps™ simplify the process by automatically validating evidence, routing issues to the right people, and generating compliance reports. Meanwhile, Censinet AI™ speeds up security questionnaires and creates automatic documentation summaries, cutting down the time needed for assessments without compromising accuracy.
Importantly, these systems don’t eliminate human judgment. Risk teams remain involved, configuring rules and reviewing processes to ensure automation supports decision-making instead of replacing it. For devices under IEC 62304 safety classifications (e.g., Class C devices, which pose risks of death or serious injury), automated tools flag high-priority vulnerabilities and route them to designated reviewers for final approval [11]. This approach ensures risks are identified faster, without sacrificing the thoroughness needed to protect patients. Additionally, platforms like Censinet RiskOps™ support real-time monitoring, offering a comprehensive view of ongoing risks.
Monitor and Benchmark Cybersecurity Performance
Once risk assessments are automated, consistent monitoring becomes the next critical step. A centralized platform offers real-time insights into your cybersecurity posture, consolidating data on vulnerabilities, patch statuses, and compliance gaps into user-friendly dashboards. For example, Censinet RiskOps™ acts as a command center, providing the oversight necessary to manage postmarket surveillance for distributed devices - an essential aspect of current FDA guidance [1].
Benchmarking capabilities add another layer of value, allowing you to compare your performance against industry standards and peer organizations. This helps prioritize improvements and demonstrate compliance to regulators. By joining collaborative risk networks and Information Sharing and Analysis Organizations (ISAOs), you can share vulnerability data with the FDA and other manufacturers, reinforcing security across the healthcare ecosystem [1]. Continuous monitoring is not just about compliance - it’s essential for safeguarding patient safety and ensuring secure updates throughout a device’s lifecycle.
Conclusion
Securing medical device software updates isn’t just a technical requirement - it’s essential for protecting patients and meeting regulatory demands. A multi-layered approach works best: start with thorough risk assessments and maintain an SBOM to keep tabs on every software component. Use protocols like TLS 1.3 and mTLS to safeguard updates, and rigorously test to catch vulnerabilities before they emerge.
Stay aligned with FDA requirements by developing strong cybersecurity plans [12]. Incorporate coordinated vulnerability disclosure (CVD) practices to streamline how vulnerabilities are reported and resolved.
Managing a growing network of connected devices often calls for automation. Tools like Censinet RiskOps™ can simplify the process by automating risk assessments, tracking performance, and managing risks from third-party vendors. These platforms aren’t replacements for human input - they’re designed to amplify it, ensuring critical issues reach the right people while maintaining the necessary oversight to keep patients safe.
FAQs
What makes a medical device software update “secure”?
A medical device software update is considered secure when it addresses vulnerabilities through verified patching methods, maintains continuous risk management, and aligns with FDA cybersecurity guidelines. This involves adopting secure development techniques, monitoring for potential threats, and promptly reporting vulnerabilities. These steps are key to safeguarding patient safety, protecting sensitive information, and ensuring the device continues to function as intended.
How do SBOMs help prevent vulnerable components from slipping into updates?
SBOMs, or Software Bills of Materials, offer a clear view of all the software components within a medical device. This transparency allows manufacturers to spot and address vulnerabilities before deploying updates. By keeping an up-to-date SBOM, manufacturers can actively monitor potential risks, prioritize patches effectively, and ensure that updates include only secure components. This not only helps meet regulatory requirements but also minimizes the chance of introducing security flaws into medical devices.
When should an update be delayed to avoid patient safety risks?
According to the FDA's guidance, updates should only be delayed if they pose a risk to patient safety or could interfere with critical operations. Before deploying patches, thorough testing and validation are crucial to ensure they don’t introduce new vulnerabilities or cause device malfunctions. A risk-based approach to patching helps prioritize updates based on the severity of the vulnerability and the importance of the device. In some cases, delays might be unavoidable, particularly if testing isn’t finished or if rolling out the update could disrupt essential clinical functions, putting patient safety at risk.
Related Blog Posts
- 7 Critical Medical Device Security Risks in Healthcare
- Best Practices for FDA IoT Cybersecurity Compliance
- Why Patch Validation Matters for Medical Devices
- FDA Cybersecurity Guidance: Medical Device Reporting Rules
{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What makes a medical device software update “secure”?","acceptedAnswer":{"@type":"Answer","text":"<p>A medical device software update is considered <strong>secure</strong> when it addresses vulnerabilities through verified patching methods, maintains continuous risk management, and aligns with FDA cybersecurity guidelines. This involves adopting secure development techniques, monitoring for potential threats, and promptly reporting vulnerabilities. These steps are key to safeguarding patient safety, protecting sensitive information, and ensuring the device continues to function as intended.</p>"}},{"@type":"Question","name":"How do SBOMs help prevent vulnerable components from slipping into updates?","acceptedAnswer":{"@type":"Answer","text":"<p>SBOMs, or Software Bills of Materials, offer a clear view of all the software components within a medical device. This transparency allows manufacturers to spot and address vulnerabilities <strong>before deploying updates</strong>. By keeping an up-to-date SBOM, manufacturers can actively monitor potential risks, prioritize patches effectively, and ensure that updates include only secure components. This not only helps meet regulatory requirements but also minimizes the chance of introducing security flaws into medical devices.</p>"}},{"@type":"Question","name":"When should an update be delayed to avoid patient safety risks?","acceptedAnswer":{"@type":"Answer","text":"<p>According to the FDA's guidance, updates should only be delayed if they pose a risk to patient safety or could interfere with critical operations. Before deploying patches, thorough testing and validation are crucial to ensure they don’t introduce new vulnerabilities or cause device malfunctions. A risk-based approach to patching helps prioritize updates based on the severity of the vulnerability and the importance of the device. In some cases, delays might be unavoidable, particularly if testing isn’t finished or if rolling out the update could disrupt essential clinical functions, putting patient safety at risk.</p>"}}]}
Key Points:
Why do medical device software updates represent a uniquely high-stakes security challenge compared to general enterprise software updates?
- Patient safety consequences are direct and immediate — A compromised or malfunction-introducing software update on a medical device can alter dosing calculations, corrupt diagnostic outputs, disable monitoring alerts, or cause device failures during life-critical clinical procedures. The consequence of a bad update on a ventilator, infusion pump, or cardiac monitor is not a system outage — it is potential patient harm or death.
- Device longevity creates multi-decade vulnerability windows — Medical devices remain in clinical use for 10 to 15 years, far outlasting the support lifecycles of their software components. A device deployed in 2015 running software whose vendor support ended in 2020 cannot receive security patches for the vulnerabilities discovered in 2024, creating permanent exposure that accumulates over the device's operational life.
- 99% of healthcare organizations have known device vulnerabilities — The near-universal presence of known vulnerabilities across healthcare device portfolios is not a compliance failure — it reflects the structural challenge of maintaining patch currency across thousands of heterogeneous devices with varying update mechanisms, regulatory constraints, and clinical availability windows.
- Supply chain attacks targeting update mechanisms are a proven vector — The 2020 SolarWinds attack infected 18,000 organizations by embedding malware in an OTA software patch — demonstrating that the update mechanism itself is a high-value attack target. For medical devices, where updates are pushed across entire device fleets, compromising the update server or distribution channel is potentially more consequential than compromising any individual device.
- Only 22% of healthcare organizations run up-to-date software across all equipment — The gap between the known need for software updates and the actual update rate reflects the operational challenges of coordinating maintenance windows, clinical continuity requirements, regulatory change control processes, and manufacturer-provided patch availability — challenges that security frameworks must account for rather than ignore.
- $9.8 million False Claims Act settlement establishes financial consequences for misrepresented cybersecurity — The early 2025 DOJ settlement with Illumina following allegations of misrepresented cybersecurity capabilities for federally funded sequencing platforms demonstrates that medical device cybersecurity failures carry not only regulatory consequences but direct financial liability under federal procurement law.
What risk assessment and SBOM practices are required before deploying medical device software updates?
- Complete device inventory as the prerequisite for all assessment activity — Risk assessment cannot be performed for devices that are not inventoried. A complete inventory of all connected medical devices, including device type, software version, network connectivity, and clinical function, is the foundational requirement for any systematic vulnerability management program.
- CVSS scoring combined with CISA KEV cross-referencing for prioritization — The Common Vulnerability Scoring System provides a structured methodology for categorizing vulnerabilities by severity and exploitability. Cross-referencing CVSS findings against the CISA Known Exploited Vulnerabilities catalog identifies which vulnerabilities are being actively exploited in the wild — a prioritization dimension that CVSS scores alone do not capture.
- Third-party component assessment as a supply chain vulnerability control — Third-party components including open-source libraries, external software dependencies, and off-the-shelf applications introduce supply chain vulnerabilities that are not visible through direct device testing alone. The March 2022 FDA guidance on PTC Axeda agent vulnerabilities — recommending upgrade to Version 6.9.2 build 1049 or higher — illustrates that third-party components in medical devices can become active patient safety risks that require immediate remediation.
- SBOM as the living vulnerability tracking instrument — An SBOM listing every software component with supplier name, component name, version, unique identifier, dependency relationships, author, and timestamp enables continuous vulnerability tracking by cross-referencing component identifiers against the National Vulnerability Database. Integrating SBOM generation into CI/CD pipelines ensures that every update automatically triggers vulnerability scanning against the current component inventory.
- Machine-readable SPDX or CycloneDX format as the FDA-required standard — SBOMs must be provided in machine-readable formats — SPDX or CycloneDX — to satisfy FDA premarket submission requirements under Section 524B. The FDA can reject premarket submissions that lack sufficient SBOM documentation, making SBOM format compliance a market access requirement rather than an operational preference.
- Controlled vs. uncontrolled risk classification for update prioritization — Classifying vulnerabilities as controlled risk — low likelihood of causing harm — or uncontrolled risk — high potential for patient safety or data integrity impact — enables risk-based prioritization that allocates remediation resources to the vulnerabilities with the highest patient harm potential rather than applying uniform urgency across all findings.
What technical architecture is required to secure over-the-air medical device software update delivery?
- Three foundational principles: authenticity, integrity, and confidentiality — Secure OTA update delivery rests on three requirements: authenticity ensures updates originate from a trusted source and have not been substituted; integrity verifies that update content has not been modified in transit; confidentiality prevents unauthorized access to update packages that could enable reverse-engineering or intellectual property theft.
- Cryptographic firmware signing with HSM-protected private keys — Firmware images must be cryptographically signed using a private key stored in a Hardware Security Module that ensures the key never leaves hardware in plaintext. The corresponding public key on the device verifies the signature before installation proceeds. An unsigned or invalid-signature update must be rejected automatically — not flagged for manual review.
- TLS 1.3 transmission with JWS signing and SHA-256 integrity verification — TLS 1.3 provides the secure transmission channel for update delivery with mandatory forward secrecy. JSON Web Signature using RFC 7515 provides the signing standard for update manifests, and SHA-256 hash verification confirms that the downloaded binary matches the manufacturer-distributed version before installation begins.
- Anti-rollback protection through tamper-proof version storage — Storing the current firmware version in tamper-proof storage — hardware fuses or equivalent mechanisms — prevents attackers from rolling back devices to earlier firmware versions with known vulnerabilities. Anti-rollback protection is a critical defense against downgrade attacks that exploit the difference between current security posture and the device's historical vulnerability surface.
- A/B partition scheme for update reliability and safety — An A/B partition architecture writes incoming updates to an inactive storage partition and activates the new firmware only after successful integrity and signature verification. If verification fails, the device remains on the current firmware version without interruption. This architecture eliminates the risk of partial update installation leaving devices in an inconsistent state during clinical operation.
- Update server hardening as the highest-priority infrastructure security requirement — The risk of compromising the OTA update server and pushing malicious firmware to an entire device fleet is greater than the risk of compromising any individual device. Update server and cloud infrastructure must be hardened against unauthorized access through network isolation, multi-factor authentication, access logging, and automated monitoring for anomalous activity — the infrastructure security posture that makes secure update delivery trustworthy at fleet scale.
What FDA compliance documentation and regulatory obligations govern the secure software update lifecycle for connected medical devices?
- Section 524B statutory authority and Refuse to Accept enforcement — Section 524B of the FD&C Act has required cybersecurity standards for all internet-connected medical devices since March 29, 2023. The FDA's Refuse to Accept policy began rejecting noncompliant premarket submissions on October 1, 2023, and noncompliance with postmarket requirements constitutes a prohibited act under Section 301(q) — establishing enforcement mechanisms at both the market access and ongoing compliance levels.
- Cybersecurity impact classification determining documentation requirements — The FDA requires manufacturers to classify all software updates based on whether they affect cybersecurity, with the classification determining the level of premarket or postmarket documentation required. Changes that affect cybersecurity require more rigorous documentation than those that do not, making accurate classification a compliance-critical judgment rather than an administrative formality.
- SPDF documentation as evidence of lifecycle security integration — The Secure Product Development Framework record must document processes for design, development, release, and support across the entire product lifecycle. The FDA's stated goal is to manufacture safe, effective, trustworthy, and resilient devices — and SPDF documentation demonstrates that security was a deliberate and managed discipline throughout development rather than a submission-time consideration.
- CVD policy as a mandatory postmarket requirement — Coordinated Vulnerability Disclosure is mandatory under Section 524B, requiring published contact information for vulnerability reporting, clear timelines for validating and addressing reported vulnerabilities, and structured collaboration with security researchers, healthcare facilities, and regulatory bodies. CVD is not merely a best practice — it is a legal obligation with financial repercussions for noncompliance.
- Device labeling as a compliance and patient safety requirement — Device labeling must provide clear instructions for securely configuring and updating the device, and must include contact information for vulnerability reporting under the CVD requirement. Inadequate or misleading labeling can result in a device being classified as misbranded — a regulatory finding with its own enforcement consequences.
- Alignment with ANSI/AAMI SW96, AAMI TIR57, and IEC 81001-5-1 — The FDA recommends alignment with recognized industry standards to demonstrate compliance. ANSI/AAMI SW96 covers security risk management for medical device software, AAMI TIR57 provides the cybersecurity risk management framework referenced in FDA premarket guidance, and IEC 81001-5-1 addresses health software and health IT security activities in the product lifecycle.
What testing and validation practices are required to ensure medical device software updates do not introduce new vulnerabilities or patient safety risks?
- Risk-based patch categorization before testing begins — Not every patch carries the same urgency. Categorizing updates as controlled risk or uncontrolled risk before testing allows resources to be allocated proportionally, with uncontrolled risk updates — those with high patient safety or data integrity implications — receiving the most rigorous validation treatment.
- IEC 62304 Class C coverage requirements for high-risk devices — For medical device software classified as IEC 62304 Class C — software whose failure could cause death or serious injury — manufacturers should target 100% statement coverage, branch coverage, and modified condition/decision coverage as the testing baseline. These coverage requirements ensure that the update validation process examines every execution path in the updated software.
- Bidirectional traceability linking requirements to test cases — Bidirectional traceability connects requirements, design specifications, code modules, and test cases so that every security requirement is demonstrably tested and every code change is traceable back to its originating requirement. This traceability matrix provides the audit trail that FDA compliance documentation and quality assurance processes require.
- Controlled environment validation before production deployment — All updates must be validated in a controlled environment that mirrors production conditions before deployment to live clinical devices. Testing in a representative environment identifies integration issues, performance impacts, and unintended interactions with connected systems before patients are exposed to the updated software.
- Development and testing backdoor verification — Backdoors created for development or testing purposes must be confirmed disabled in production firmware before any update is deployed. A development backdoor present in production creates a privileged access path that bypasses normal authentication and security controls — one of the most exploitable vulnerabilities in deployed medical device software.
- Post-deployment validation as a continuous activity — Validation does not end at deployment. Continuous monitoring of device performance and security posture following update deployment detects issues that pre-deployment testing did not surface under real-world clinical conditions, enabling rapid response before patient harm occurs.
How do Censinet RiskOps™ and Censinet AI™ address the scale, complexity, and human oversight requirements of medical device software update security?
- Centralized vulnerability tracking across the full device ecosystem — Healthcare organizations managing hundreds or thousands of connected medical devices cannot track vulnerability status, patch availability, and remediation progress through manual processes at operational scale. Censinet RiskOps™ centralizes this tracking across the full device ecosystem, providing a real-time view of vulnerability and patch status that manual spreadsheet-based tracking cannot sustain.
- AI-accelerated assessment without sacrificing human judgment — Censinet AI™ accelerates security questionnaires and generates automatic documentation summaries, reducing the time required for device assessments without replacing the human judgment that patient safety decisions require. Risk teams configure the rules, review the findings, and retain final approval authority — automation amplifies human capacity rather than substituting for it.
- IEC 62304 Class C escalation routing — For devices classified under IEC 62304 Class C whose failure could cause death or serious injury, Censinet RiskOps™ flags high-priority vulnerabilities and routes them to designated reviewers for final approval. This escalation architecture ensures that the highest-consequence risk decisions receive the human review they require rather than being processed through automated workflows without oversight.
- Benchmarking against peer organizations for relative posture visibility — Internal assessment alone cannot reveal whether an organization's medical device cybersecurity posture is strong, average, or inadequate relative to industry peers. Censinet RiskOps™ benchmarking capabilities enable comparison against industry standards and peer healthcare organizations, supporting evidence-based investment decisions and demonstrating compliance posture to regulators.
- Collaborative risk network for FDA and manufacturer vulnerability sharing — Participating in collaborative risk networks and ISAOs enables healthcare organizations to share vulnerability data with the FDA and other manufacturers, contributing to and benefiting from the collective intelligence that makes systemic vulnerability identification faster and more comprehensive than any single organization's internal monitoring can achieve.
- Postmarket surveillance support as an FDA compliance function — FDA postmarket surveillance for connected medical devices requires continuous monitoring of vulnerability emergence and remediation status across the device fleet. Censinet RiskOps™ provides the operational infrastructure for this ongoing surveillance requirement — converting postmarket compliance from a documentation exercise into a continuously operating risk management function.
